Development, valley of death

The development is ongoing strongly and the signs are good. 

https://meetings-api.hematology.org/api/abstract/vmpreview/296056  

Publication Number: 236 

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study 

"Bexmarilimab enhances macrophage antigen presentation and T cell activation. Thus, bexmarilimab may favourably alter the dysregulated BM immune microenvironment in mTP53 MDS. Simultaneously, bexmarilimab can increase the efficacy of cytotoxic agents, such as HMAs, by targeting Clever-1 on malignant blasts and altering energy production of the malignant cells." 

Authors:
Amer Zeidan (1), Anthony Stein (2), Johanna Rimpiläinen (3), Marja Pyörälä (4), Timo Siitonen (5), Brian Ball (2), Mikko Myllymäki (6), Joshua Zeidner (7), Dr. Emma Searle (8), Ruth Witherall (9), Petri Bono (10), Aneel Nimba (10), Joab Williamson (10), Sofia Aakko (10), Maija Hollmén (10), (11), Mika Kontro (6), (12), Naval Daver (13) 

1 Yale University and Yale Comperehensive Cancer Center, New Haven, CT, United States, 2 City of Hope Cancer Center, Duarte, CA, United States, 3 Tampere University Hospital, Deparment of Internal Medicine, Tampere, Finland, 4 Kuopio University Hospital, Kuopio, Finland, 5 Cancer Center, Oulu University Hospital, Oulu, Finland, 6 Helsinki University Hospital, Comperehensive Cancer Center, Deparment of Hematology, Helsinki, Finland, 7 University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States, 8 The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom, 9 Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom, 10 Faron
Pharmaceuticals Ltd, Turku, Finland, 11 University of Turku, MediCity Research Laboratory and InFLAMES Flagship, Turku, Finland, 12 University of Helsinki, Helsinki, Finland, 13 The University of Texas MD Anderson Cancer Center, Houston, TX, United States 

Signs, the best of: Comprehensive co-operations internationally and nationally.

For example: University of Texas MD Anderson Cancer Center, Houston, TX - number one in clinical tests in the world - and Mr. Naval Daver's comment on an eve of a conference: "A NEW DAWN "

Are we passing the valley of death?

https://venturecapital.nl/the-valley-of-death/ 

  

Healthy company - healthy investor